SCHEMBL6014575

SCHEMBL6014575

N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCC1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.96
MAP3K20 Q9NYL2 2/20 0.96
RIPK3 Q9Y572 2/20 0.96
KDR P35968 17/20 0.88
ABCB1 P08183 1/20 0.58
CIT O14578 1/20 0.55
MAP3K7 O43318 1/20 0.55
RIPK2 O43353 1/20 0.55
STK10 O94804 1/20 0.55
MAP4K4 O95819 1/20 0.55
ABL1 P00519 1/20 0.55
EGFR P00533 1/20 0.55
RAF1 P04049 1/20 0.55
LCK P06239 1/20 0.55
FYN P06241 1/20 0.55
CSF1R P07333 1/20 0.55
YES1 P07947 1/20 0.55
LYN P07948 1/20 0.55
HCK P08631 1/20 0.55
PDGFRB P09619 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rivoceranib SCHEMBL29360856 0.98 RET (1.00) RETMAP3K20RIPK3KDRABCB1
Rivoceranib SCHEMBL1814966 0.98 RET (1.00) RETMAP3K20RIPK3KDRABCB1
SCHEMBL6014666 0.97 RET (0.98) RETMAP3K20RIPK3KDRABCB1
SCHEMBL6014552 0.96 RET (0.93) RETMAP3K20RIPK3KDRABCB1
Rivoceranib SCHEMBL21847695 0.94 KDR (1.00) RETMAP3K20RIPK3KDRABCB1
SCHEMBL31362718 0.91 RET (0.88) RETMAP3K20RIPK3KDRABCB1
SCHEMBL31362733 0.89 RET (0.83) RETMAP3K20RIPK3KDRABCB1
SCHEMBL31362698 0.89 RET (0.83) RETMAP3K20RIPK3KDRABCB1
SCHEMBL6014513 0.87 RET (0.73) RETMAP3K20RIPK3KDRABL1
SCHEMBL6014554 0.85 RET (0.72) RETMAP3K20RIPK3KDRABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 EP claimed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 US claimed
EP-1633712-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Chen, Guoqing Paul (US) 2006-03-15 EP claimed
WO-2005000232-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2005-01-06 WO claimed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 US claimed
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 EP disclosed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 US disclosed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors TEK, FLT1, VEGFA RET 2382/4885MAP3K20 2688/4885RIPK3 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.